Galmed Pharmaceuticals Ltd.(GLMD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Galmed Pharmaceuticals Ltd. (GLMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. GLMD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of GLMD by reported 13-F value include CITADEL ADVISORS, XTX Topco Ltd, TWO SIGMA SECURITIES, based on the most recent SEC filings. GLMD trades on the Nasdaq exchange and files with the SEC under CIK 1595353. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Galmed Pharmaceuticals Ltd. directly from SEC EDGAR.

Net Income

$-4.8M

GLMD key financials by period

Galmed Pharmaceuticals Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 201820-F$2.0M——
FY 201720-F$1.1M——
FY 201620-F$467.0K——

Institutions holding GLMD

Institutional investors reporting a position in Galmed Pharmaceuticals Ltd. on SEC Form 13F.
InstitutionSharesValueReported
CITADEL ADVISORS86,851$48.3K2026-06-30
XTX Topco Ltd15,015$8.4K2026-06-30
TWO SIGMA SECURITIES11,012$6.1K2026-06-30
SBI Securities , Ltd.66$37.002026-06-30
MORGAN STANLEY56$31.002026-06-30
WELLS FARGO & COMPANY43$24.002026-06-30
HRT FINANCIAL42,090$23.002026-06-30
Federation des caisses Desjardins du Quebec14$8.002026-06-30
OSAIC5$2.002026-06-30
Allworth Financial2$2.002026-06-30
SEC EDGAR: CIK 1595353 →
GLMD

Galmed Pharmaceuticals Ltd.

GLMD
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q4 2025
EDGAR

$-4.82M

EPS (Diluted)

Q4 2025
EDGAR

$0.92

Top Institutional Holders

as of Q2 2026
$62.9K total
CITADEL ADVISORS LLC
$48.3K+663.1%
XTX Topco Ltd
$8.4K-33.0%
TWO SIGMA SECURITIES, LLC
$6.1K-8.0%
SBI Securities Co., Ltd.
$37+312.5%
MORGAN STANLEY
$31-64.3%
WELLS FARGO & COMPANY/MN
$240.0%
HRT FINANCIAL LP
$23New
Federation des caisses Desjardins du Quebec
$80.0%
OSAIC HOLDINGS, INC.
$20.0%
Allworth Financial LP
$20.0%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…